BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Calliditas Therapeutics AB (publ):
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-09-11 7:42 pm Sale | 2024-09-02 | 13G | Calliditas Therapeutics AB (publ) CALT | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -6,260,311 (Position Closed) | Filing |
| 2023-02-14 11:50 am Sale | 2022-12-31 | 13G | Calliditas Therapeutics AB (publ) CALT | BIOTECHNOLOGY VALUE FUND L P | 6,260,311 10.500% | -1,171,251 (-15.76%) | Filing |
| 2020-11-12 5:11 pm Purchase | 2020-11-09 | 13G | Calliditas Therapeutics AB (publ) CALT | BIOTECHNOLOGY VALUE FUND L P | 7,431,562 14.900% | 2,650,000 (+55.42%) | Filing |
| 2020-06-08 10:27 am Purchase | 2020-06-05 | 13G | Calliditas Therapeutics AB (publ) CALT | BIOTECHNOLOGY VALUE FUND L P | 4,781,562 9.700% | 4,781,562 (New Position) | Filing |